Technical Analysis for RGNX - REGENXBIO Inc.

Grade Last Price % Change Price Change
grade C 48.19 -1.85% -0.91
RGNX closed down 1.85 percent on Friday, January 17, 2020, on 89 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical RGNX trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Stochastic Sell Signal Bearish 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
NR7 Range Contraction -1.85%
Upper Bollinger Band Walk Strength -1.85%
Above Upper BB Strength -1.85%
Overbought Stochastic Strength -1.85%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


REGENXBIO Inc., a biotechnology company, focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company's development programs include RGX-501, a product candidate for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111, a product candidate for the treatment of Mucopolysaccharidosis Type I, which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system. Its programs also include RGX-121, a product candidate for the treatment of Mucopolysaccharidosis Type II; RGX-314, a product candidate for the treatment of wet age-related macular degeneration; and RGX-321, a product candidate for the treatment of X-linked retinitis pigmentosa. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Biotechnology Biology Emerging Technologies Gene Therapy Molecular Biology Genetics Medical Genetics Applied Genetics Wet Age Related Macular Degeneration Retinitis Pigmentosa Gene Delivery Adeno Associated Virus Homozygous Familial Hypercholesterolemia Iduronidase X Linked Retinitis Pigmentosa

Is RGNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 63.21
52 Week Low 30.38
Average Volume 460,822
200-Day Moving Average 43.07
50-Day Moving Average 41.37
20-Day Moving Average 42.71
10-Day Moving Average 44.60
Average True Range 2.14
ADX 21.83
+DI 31.69
-DI 12.05
Chandelier Exit (Long, 3 ATRs ) 43.68
Chandelier Exit (Short, 3 ATRs ) 44.17
Upper Bollinger Band 48.64
Lower Bollinger Band 36.77
Percent B (%b) 0.96
BandWidth 27.80
MACD Line 1.73
MACD Signal Line 0.92
MACD Histogram 0.8073
Fundamentals Value
Market Cap 1.49 Billion
Num Shares 30.9 Million
EPS -2.69
Price-to-Earnings (P/E) Ratio -17.91
Price-to-Sales 99.62
Price-to-Book 4.15
PEG Ratio 1.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 51.05
Resistance 3 (R3) 51.36 50.73 50.57
Resistance 2 (R2) 50.73 50.00 50.57 50.41
Resistance 1 (R1) 49.46 49.55 49.14 49.14 50.25
Pivot Point 48.82 48.82 48.66 48.66 48.82
Support 1 (S1) 47.55 48.09 47.23 47.24 46.13
Support 2 (S2) 46.92 47.64 46.76 45.97
Support 3 (S3) 45.65 46.92 45.81
Support 4 (S4) 45.33